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To estimate multipliers linking surveillance of salmonel-
losis, campylobacteriosis, and Shiga toxin–producing Es-
cherichia coli (STEC) infections to community incidence, we 
used data from a gastroenteritis survey and other sources. 
Multipliers for severe (bloody stool/long duration) and milder 
cases were estimated from the component probabilities of 
doctor visit, stool test, sensitivity of laboratory test, and re-
porting to surveillance system. Pathogens were classiﬁ  ed 
by the same severity criteria and appropriate multipliers ap-
plied. Precision of estimates was quantiﬁ  ed by using simu-
lation techniques to construct 95% credible intervals (CrIs). 
The multiplier for salmonellosis was estimated at 7 (95% 
CrI 4–16), for campylobacteriosis at 10 (95% CrI 7–22), and 
for STEC at 8 (95% CrI 3–75). Australian annual community 
incidence rates per 100,000 population were estimated as 
262 (95% CrI 150–624), 1,184 (95% CrI 756–2,670), and 
23 (95% CrI 13–54), respectively. Estimation of multipliers 
allows assessment of the true effects of these diseases and 
better understanding of public health surveillance.
T
he primary aims of laboratory-based surveillance of 
Salmonella, Campylobacter, and Shiga toxin–produc-
ing Escherichia coli (STEC) infections in industrialized 
countries are to detect outbreaks and to monitor changes 
in incidence over time. For laboratory-based surveillance, 
a person with diarrhea must visit a doctor, have an appro-
priate stool sample transported to the laboratory correctly, 
have a positive laboratory test for a notiﬁ  able disease, and 
have this result reported to the surveillance system. Be-
cause many persons do not visit a doctor or have a stool 
sample taken when they have diarrhea, surveillance data 
do not capture all disease and represent only a fraction of 
disease occurring in the community. However, knowledge 
of the absolute number of cases in the community would be 
extremely useful for setting public health policy and esti-
mating the cost of illness.
Studies that have estimated community incidence have 
used various methods. These include: capture-recapture 
(1), Delphi or expert consensus (2), outbreak reports (3,4), 
community-based cohort studies of diarrheal disease (5), 
and estimation of multipliers of surveillance data by using 
additional data (6). Although cohort studies are the most 
direct way of estimating diarrheal illness in the commu-
nity, they are expensive and are subject to limitations for 
estimating the incidence of pathogen-speciﬁ  c  infections 
because of the small numbers of cases (7,8).
This article describes how we estimated multipliers to 
apply to laboratory surveillance data to estimate commu-
nity incidence, including estimation of precision. We used 
data collected in a survey of gastroenteritis and data from 
case-control studies and from quality assurance of labora-
tory testing to estimate the major component parts of the 
multipliers. The major components are the proportion of 
case-patients who visit a doctor, the proportion of these 
patients who have a stool sample sent to the laboratory 
for testing, the sensitivity of the laboratory test to cor-
rectly identify a pathogen, and the proportion of positive 
results that are reported to surveillance by laboratories. 
These component parts were then used to estimate the 
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overall multipliers, and the precision of these estimates 
was determined.
In 2005, a total of 7,720 cases of salmonellosis, 15,313 
cases of campylobacteriosis, and 85 cases of STEC infec-
tion were reported to the Australian National Notiﬁ  able 
Diseases Surveillance System. The speciﬁ  c objective of 
this study was to estimate the multipliers to apply to Sal-
monella, Campylobacter, and STEC infections reported to 
national surveillance and to estimate the community inci-
dence of these conditions in Australia.
Methods
Overview
The fraction of community cases reported to surveil-
lance was derived from the probability of a case-patient 
in the community visiting a doctor, having a stool sample 
taken, having a positive laboratory test, and having the case 
reported to surveillance (Figure). At every step a proportion 
of cases from the previous step are lost, resulting in only a 
fraction of cases being reported (the notiﬁ  cation fraction).
The notiﬁ  cation fraction (NF) is equal to the product 
of the component probabilities; that is, NF = Pd × Ps × Pl 
× Pn (Figure), where Pd = probability that a case-patient 
in the community visits a doctor, Ps = probability that a 
case-patient seen by a doctor has a stool sample taken, Pl = 
probability that a laboratory correctly identiﬁ  es the patho-
gen in the stool sample, and Pn = probability that a positive 
result is reported to health authorities. The reciprocal of the 
notiﬁ  cation fraction is the multiplier M (M = 1/NF).
The probabilities of visiting a doctor and of having stool 
tested are likely to be greater when illness is more severe. 
We therefore assessed the inﬂ  uence of different symptoms 
on the likelihood of gastroenteritis patients visiting a doctor 
and having a stool sample taken. Inﬂ  uential symptoms were 
used to classify gastroenteritis cases by severity, and multi-
pliers were calculated for the different severity categories. 
The 3 infections of interest—salmonellosis, campylobacte-
rosis, and STEC infection—were then classiﬁ  ed by using 
the same categories so that appropriate multipliers could 
be applied, based on the severity of the particular illness. 
Uncertainty in the estimates was estimated by using simu-
lation techniques to derive a 95% credible interval (95% 
CrI), akin to methods used in Bayesian estimations.
Data Sources
We derived our estimates from data already available 
in Australia on diarrhea, salmonellosis, campylobacterio-
sis, and STEC infection (Table 1).
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Figure. Sequential steps for notiﬁ  cation to a surveillance system. 
The probability of progressing in the sequential steps in the 
surveillance system is represented by P. GP, general practitioner.
Table 1. Data sources used to assess under-reporting of Salmonella, Campylobacter, and STEC infections, Australia, 2001–2005* 
Information Data sources
Symptoms that predicted visiting a doctor and having stool tested 
(“predictor symptoms”) used to adjust calculations for severity of 
illness 
Australian National Gastroenteritis Survey (NGS) conducted 
across Australia during 2001 and 2002 (9)
Probability of a case-patient in the community visiting a doctor  NGS 
Probability of a case-patient seen by a doctor having stool tested NGS and unpublished reports of 2 surveys of GP treatment and
management practices for gastroenteritis in 2003/2004 and 2005 
in 2 Australian states (10,11)
Probability of correctly identifying Salmonella and Campylobacter
in stool samples by laboratories 
Royal College of Pathologists Australasia, Quality Assurance 
Programs Pty Limited, Microbiology QAP Results, 2001 (12)
Probability of a positive result being reported to health authorities Discussions with OzFoodNet epidemiologists  
Symptom profiles for reported cases of salmonellosis  Unpublished case-control study data from the Hunter Public 
Health Unit, NSW Australia (1997–2000), and OzFoodNet sites 
(2000–2003)  
Symptom profiles on reported cases of campylobacteriosis  Unpublished case control study data from the Hunter Public 
Health Unit, NSW Australia (1997–2000), and OzFoodNet sites 
(2000–2003)  
Information on reported cases of STEC, and laboratory sensitivity 
of detecting STEC from fecal samples 
Unpublished data from OzFoodNet study on STEC in South 
Australia, 2003–2005 
Number of notifications of campylobacteriosis, salmonellosis, and 
STEC infection. 
National Notifiable Diseases Surveillance System  (13)
Australian midyear population for 2005  Australian Bureau of Statistics (14)
*STEC, Shiga toxin–-producing Escherichia coli; GP, general practitioner; QAP, quality assurance program. Further details of how data were used are 
shown in the online Technical Appendix, available from www.cdc.gov/EID/content/14/10/1601-Techapp.pdf. Salmonella, Campylobacter, and Shiga Toxin–producing Infections
Estimation of Symptom-speciﬁ  c Probabilities 
for Visiting a Doctor and Having a Stool Test 
(Pd and Ps)
The component probabilities Pd and Ps were estimated 
from the National Gastroenteritis Survey (NGS) conducted 
in 2002. The telephone survey, using a random stratiﬁ  ed 
sample from all states in Australia, included a total sample 
of 6,087 persons who were asked about diarrheal illness 
they had experienced in the previous 4 weeks. Respondents 
with chronic illness with diarrhea were not counted as case-
patients unless they identiﬁ  ed their symptoms as different 
than usual. Case-patients were asked details about their ill-
ness and days of duration of symptoms (9). The case deﬁ  ni-
tion of diarrheal illness was the following: at least 3 loose 
stools in 24 hours (excluding those persons who report a 
noninfectious cause of their diarrhea because of pregnancy, 
alcohol use, chronic illness, or medications) and duration 
<28 days.
Adjusting Component Probabilities 
for Severity of Illness
To calculate improved pathogen-speciﬁ  c  estimates 
rather than estimates of underreporting of all gastroenteri-
tis, we estimated multipliers from NGS for gastroenteritis 
of varying severity. The proportion of cases in correspond-
ing severity categories was then estimated for the 3 differ-
ent pathogens by using other data from case-control studies 
(Table 1). The appropriate multipliers could then be applied 
according to the average severity of illness.
Symptoms of severity that predicted whether the per-
son with gastroenteritis visited a doctor were identiﬁ  ed 
from NGS by using multivariable logistic regression. The 
following conditions were evaluated: duration of illness, 
cramps, vomiting, nausea, blood in the stool, headache, 
respiratory symptoms (coughing, sneezing, sore throat), 
fever, body aches, loss of appetite, and stiff neck. Age and 
sex of the patients were also considered. A p value<0.05 
was considered statistically signiﬁ  cant.
Because the number of case-patients who had stool 
tests was small in the gastroenteritis survey (n = 15), uni-
variate regression was used to identify severity symptoms 
that predicted whether a doctor ordered a stool test (statisti-
cal signiﬁ  cance p<0.1). Additional information from a ran-
dom sample of general practitioners (GPs) from 2 states of 
Australia on the treatment of diarrheal disease was used to 
identify severity symptoms that prompted doctors to order 
a stool test (10,11). Data were stratiﬁ  ed by symptom cat-
egories that were statistically signiﬁ  cant determinants for 
both visiting a doctor and having a stool test ordered. Prob-
abilities were calculated for case-patients in each symptom 
category of visiting a doctor and having stool tested.
Pathogen-speciﬁ  c Symptom Proﬁ  les
The severity symptom proﬁ  les of salmonellosis and 
campylobacterosis were developed from OzFoodNet na-
tional case-control studies based on 396 and 1,087 reported 
cases, respectively (Table 1). The STEC symptom proﬁ  le 
was based on a case-control study of 34 cases in South Aus-
tralia. The proportion of case-patients who experienced the 
predictor symptoms (i.e., symptoms that were found to pre-
dict visiting a doctor and a doctor’s ordering of stool tests) 
was calculated. From this calculation, the probabilities of 
visiting a doctor and having a stool test were estimated for 
each pathogen, weighted by severity of illness.
Sensitivity of Laboratory Testing
All fecal specimens are routinely tested for Salmonella 
and Campylobacter spp. in Australia. The sensitivities (Pl) 
of laboratory tests to detect Salmonella and Campylobacter 
spp. were obtained from quality assurance data from ≈250 
laboratories across the country (12). This sensitivity testing 
is based on inoculated samples that are transported to labo-
ratories from a central source. For STEC, data were from 
the state of South Australia, where enhanced surveillance 
exists for this pathogen. Laboratories routinely forward all 
stool samples with macroscopic blood to a reference labo-
ratory, which tests for STEC by using molecular methods 
to detect genes encoding for production of Shiga toxin 1 
and Shiga toxin 2 (15).
Reporting to Surveillance Network
The completeness of mandatory reporting to health 
departments was discussed with state epidemiologists in-
volved in OzFoodNet, Australia’s foodborne disease sur-
veillance network. Based on these discussions, we conclud-
ed that mandatory reporting to health departments has been 
virtually complete for these pathogens for several years 
preceding 2005 because of the widespread use of comput-
erized reporting practices in Australian laboratories. This 
information was used to estimate the probability for a posi-
tive result to be reported to health authorities (Pn). Formal 
validation studies on completeness of reporting were not 
available.
Uncertainty and 95% CrIs
Simulation techniques were used to quantify the de-
gree of uncertainty of the underreporting factors. The un-
certainty in our knowledge about each of Pd, Ps, and Pl was 
quantiﬁ  ed in terms of a normal distribution as this is a sim-
ple technique easily applied in different situations. How-
ever, because some data may be best simulated by using 
other distributions (such as probabilities close to 1 or 0 and 
other nonsymmetric distributions), we compared the output 
from simulations that used normal distributions with sim-
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ulations that used other distributions as indicated (online 
Technical Appendix,  available from www.cdc.gov/EID/
content/14/10/1601-Techapp.pdf). The different distribu-
tions had minimal inﬂ  uence on the outcomes, and therefore 
all simulations were conducted as normal distributions.
The mean and standard deviation were allocated to 
describe the simulations when various data sources were 
used. The mean and standard deviation of the probability of 
visiting a doctor (Pd) were estimated from the gastroenteri-
tis survey data (9). The mean and standard deviation of the 
probability of stool ordering (Ps) by GPs were quantiﬁ  ed 
by averaging results from the GP surveys conducted in the 
states of South Australia and Victoria (10,11). The mean 
and standard deviation of the sensitivity of stool testing (Pl) 
were quantiﬁ  ed by using quality assurance results from the 
2001 report (12). If a simulation produced a few negative 
values, these were treated as missing data. For each patho-
gen, a distribution was similarly determined for the symp-
tom proﬁ  les that described the proportion of cases in each 
of 6 severity categories by using data from the case-control 
studies as shown in Table 1.
For each pathogen, 1,000 observations were simulated 
from each of the distributions and were used to calculate 
1,000 estimates of the multipliers. The range between the 
2.5 and 97.5 percentiles of this empirical distribution was 
quoted as a 95% CrI for the ﬁ  nal estimates of the multipli-
ers. The parameters used in the simulations are shown in 
the online Technical Appendix tables. The software pack-
age SPSS was used for simulations (16).
Calculation of Community Incidence
The number of national notiﬁ  cations for each pathogen 
from 2000 through 2004 was used to estimate the mean and 
standard deviation of a normal distribution for the yearly 
notiﬁ  cations (Table 2). Data were adjusted for total pop-
ulation coverage for Campylobacter spp. because 1 state 
(New South Wales) does not report this pathogen. STEC 
estimates were based on information from 1 state (South 
Australia), so South Australian estimates for STEC were 
then extrapolated to the national population.
One thousand simulated values from these distribu-
tions were then multiplied by the 1,000 simulated values of 
the pathogen-speciﬁ  c multipliers to obtain 1,000 simulated 
annual incidences in the community. The median and the 
95% CrI from this empirical distribution were estimated as 
above.
Results
Estimation of Symptom-speciﬁ  c Probabilities 
for Visiting a Doctor and Having a Stool Test 
Among respondents of the NGS, 374 persons had diar-
rhea and met our case deﬁ  nition. Of these case-patients, 75 
(20%) visited a doctor for treatment, and for 15 (20%) of 
75, a stool test was ordered.
Duration of illness was the most important statistically 
signiﬁ  cant symptom that increased both the probability of 
visiting a doctor and of having a stool sample taken. The 
odds of visiting a doctor doubled with each day of duration 
(p<0.001), and the odds of having a stool test among those 
who visited a doctor was 1.5 (p = 0.005) for each day of 
duration. Blood in stool was identiﬁ  ed as a strong predictor 
for a doctor to order a stool test in both of the GP surveys, 
with 80% and 91%, respectively, of GPs in the 2 surveys 
“always or nearly always” ordering a stool test if blood was 
present (10,11). In the gastroenteritis survey, the presence 
of blood in the stool did not inﬂ  uence whether a person 
with gastroenteritis visited a doctor (odds ratio [OR] = 1.5, 
p = 0.55) but did inﬂ  uence whether a doctor ordered a stool 
test (OR = 9, p = 0.08). Fever was also statistically signiﬁ  -
cantly associated with visiting a doctor. All other variables 
were not signiﬁ  cant.
Since duration of illness was identiﬁ  ed as inﬂ  uential 
on both the patient’s visiting a doctor and on whether a 
stool test was ordered, and because blood in stool was also 
very inﬂ  uential on whether a doctor ordered a stool test, 
6 severity categories were created: 3 duration categories 
(1–2 days, 3–4 days, >5 days) for those with blood in stool, 
and the same duration categories for those without blood in 
stool. The component probabilities Pd and Ps were then cal-
culated separately for each severity category as shown in 
Table 3. Further data details are shown in the online Tech-
nical Appendix.
Because blood in stool did not predict patient’s health-
seeking behavior in the NGS, the estimates of probability 
of visiting a doctor by duration were made on the whole 
sample and then the same probabilities were applied to the 
categories of “with blood” and “without blood” in stool. 
The probability of visiting a doctor increased from 0.1 to 
0.67 as duration increased from 1–2 days to >5 days. Based 
on the surveys of GPs, we estimated that among patients 
with bloody diarrhea who visited a doctor, the probability 
of having a stool test was 0.85, regardless of the duration 
of their diarrhea. For those without blood in stool, the prob-
ability of a stool test increased from ≈0.1 to 0.4 as duration 
of illness increased.
Laboratory Testing
Quality assurance testing in 2001 showed that 100% of 
254 laboratories correctly detected Salmonella spp. from 1 
batch of fecal samples, and 233 (95%) of 246 laboratories 
identiﬁ  ed it correctly from a second batch. Of 257 laborato-
ries, 220 (86%) correctly detected Campylobacter spp.from 
1 batch of fecal samples, and 232 (95%) of 244 laborato-
ries detected it from a second batch (12). The probability 
for correct identiﬁ  cation of Salmonella spp. by laboratories 
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was therefore estimated to be 0.98 (95% CrI 0.95–1.00) 
and for identiﬁ  cation of Campylobacter spp., 0.90 (95% 
CrI 0.85–0.95).
The probability for correct STEC identiﬁ  cation by a lab-
oratory PCR was estimated to be 0.98 (95% CrI 0.95–1.00) 
(17). Macroscopic blood is the major reason for conducting 
a laboratory test to identity STEC in South Australia. Among 
those persons with STEC infection, 0.90 (95% CrI 0.85–0.95) 
of their stools are estimated to have macroscopic blood (18). 
The proportion of stools containing STEC that are identiﬁ  ed 
by laboratories in South Australia was therefore estimated as 
the product of 0.90 (95% CrI; 0.85–0.95) and 0.98 (95% CrI 
0.95–1.00) to give 0.88 (95% CrI; 0.83–0.93).
Pathogen-speciﬁ  c Multipliers
Underreporting varied considerably by severity of ill-
ness, with reporting ranging from ≈l in 2 cases for “severe 
illness” cases with blood in the stool and long duration, to 
≈1 in 150 for “mild illnesses” without blood and shorter 
duration (Table 3). For every 100 cases reported, the num-
ber in each of the 6 severity categories is shown for each 
pathogen in Table 3. Long duration is common; 83% of 
salmonellosis cases, 77% of campylobacterosis cases, 
and 74% of STEC cases lasted at least 5 days. Blood in 
stool was reported for 50%, 44%, and 86% of salmonel-
losis, campylobacteriosis, and STEC cases, respectively. 
The severity-weighted estimates of underreporting for sal-
monellosis, campylobacteriosis, and STEC infection are 
shown in Table 4. For every 100 notiﬁ  cations, an estimated 
695 (95% CrI 399–1,643) cases of salmonellosis occurred 
in the community and 1,001 (95% CrI 664–2,251) cases 
of campylobacteriosis. In South Australia, for every 100 
notiﬁ  cations of STEC, an estimated 815 cases (95% CrI 
330–7,514) occurred in the community.
The multipliers for Salmonella, Campylobacter, and 
STEC infections are thus 7 (95% CrI 4–16), 10 (95% CrI 
7–22), and 8 (95% CrI 3–75), respectively. This indicates 
that overall, including mild to severe illness, ≈85% of sal-
monellosis cases, 90% of campylobacteriosis cases, and 
88% of STEC cases are not reported.
Community Incidence of Salmonella, 
Campylobacter, and STEC Infections
In the 5 years from 2000 to 2004, the national notiﬁ  ca-
tions for Salmonella ranged from 6,196 to 7,829 each year. 
The notiﬁ  cations from all states, except New South Wales, 
for Campylobacter ranged from 13,665 to 15,622. The no-
tiﬁ  cations for STEC in the state of South Australia ranged 
from 27 to 39 from 2001 through 2004 (Table 2). The num-
ber of yearly reported cases was used to estimate the mean 
and standard deviation and then data were simulated from a 
normal distribution to give distributions of average “yearly 
notiﬁ  cation number.” The product of the yearly notiﬁ  cation 
number and the pathogen multipliers resulted in an estimate 
of the number of annual community infections of 49,843 
(95% CrI 28,466–118,518) cases of salmonellosis, 224,972 
(95% CrI 143,771–507,334) cases of campylobacteriosis, 
and 4,420 (95% CrI 2,407–10,196) cases of STEC infec-
tion. The corresponding estimates of annual incidence per 
100,000 population are salmonellosis, 262 (95% CrI, 150–
624); campylobacteriosis, 1,184 (95% CrI 756–2,670); and 
STEC infections, 23 (95% CrI 13–54).
Discussion
In this study, we were able to provide CrIs of annual 
community incidence of 3 important infections from sur-
veillance data. We used a method for determining patho-
gen-speciﬁ  c underreporting factors in Australia that has 
been deduced without the need to collect costly new data 
and includes an estimation of precision. This method is 
applicable to diseases other than infectious diarrhea, pro-
vided data on the components of the notiﬁ  cation fraction 
are available: the proportion of case-patients who visit a 
doctor, the proportion who have a laboratory test, the sen-
sitivity of the test, and the completeness of reporting of 
illness to surveillance. Even if collecting some additional 
data is necessary to estimate certain components of the 
notiﬁ  cation fraction, this collecting may be worthwhile to 
obtain the added insight into the effects of particular dis-
eases. Although knowing the incidence may not be nec-
essary for detecting outbreaks and monitoring increased 
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Table 2. Number of notifications in Australia each year for salmonellosis, campylobacteriosis, and STEC infections, 2000–2004†
Data Salmonella infections Campylobacter infections (all states except NSW)† STEC infections in SA‡
Year 
 2000 6,196 13,665 –
 2001  7,047 16,123 27
 2002  7,696 14,740 39
 2003  7,017 15,369 37
 2004  7,829 15,622 30
Mean (SD) 7,157 (651)  15,104 (946) 33.3 (5.67)
Median 7,047 15,369 34
Percentiles: 2.5, 97.5  6,278, 7,816  13,773, 16,073  27, 39 
*STEC, Shiga toxin–producing Escherichia coli; NSW, New South Wales; SA, South Australia. 
†67% of population only; adjust for population of Australia by multiplying by 1.5. 
‡7.5% of population only; adjust for population of Australia by multiplying by 13.3. RESEARCH
or decreased disease over time, this information is vitally 
important to policy makers. We consider it most important 
to furnish estimates with a measure of their precision and 
have used a simple simulation technique that is easily ap-
plied. If information is to be used in public health policy 
making, the responsible interpretation of results involves 
a realistic appreciation of potential error. Simple point es-
timates may give a misleading picture of certainty; the 
estimates of the community incidence of these foodborne 
diseases show a high degree of uncertainty that should 
be acknowledged when comparing estimates from other 
countries or times.
If this level of uncertainty is also found in other coun-
tries, then our conﬁ  dence in apparent differences may be 
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Table 3. Probabilities and underreporting factors for each category of duration of diarrhea by blood in stool, for salmonellosis,
campylobacteriosis, and STEC infections* 
Probability of:
Condition/predictor 
symptoms
(a) Case-patient 
visiting a doctor 
(95% CrI)
(b) Stool being 
tested (95% CrI)
(c) Positive stool 
results (95% CrI)
(d)
Notification
by laboratory
Probability for a 
case to be 
reported†  
(95% CrI)
Multiplier‡  
(95% CrI)
Salmonellosis
 With  blood
  1–2  d 0.10 (0.07–0.14) 0.85 (0.72–0.98) 0.98 (0.95–1.00) 1.00 0.09 (0.06–0.12) 11.39
(8.49–16.36)
    3–4 d 0.43 (0.31–0.54) 0.85 (0.72–0.98) 0.98 (0.95–1.00) 1.00 0.36 (0.25–0.46) 2.82
(2.17–3.98)
>5 d 0.67 (0.46–0.88) 0.85 (0.72–0.98) 0.98 (0.95–1.00) 1.00 0.55 (0.368–0.75) 1.81
(1.33–2.72)
 Without  blood
  1–2  d 0.10 (0.07–0.14) 0.07 (0.02–0.02) 0.98 (0.95–1.00) 1.00 0.01 (0.003–0.01) 143.29
(83.30–371.0)
    3–4 d 0.43 (0.31–0.54) 0.19 (0.071–0.36) 0.98 (0.95–1.00) 1.00 0.08 (0.010–0.16) 13.06
(6.37–67.83)
>5 d 0.67 (0.46–0.88) 0.40(0.133–0.67) 0.98 (0.95–1.00) 1.00 0.25 (0.075–0.48) 3.93
(2.10–11.92)
Campylobacteriosis 
 With  blood
  1–2  d 0.10 (0.07–0.14) 0.85 (0.72–0.98) 0.90 (0.85–0.95) 1.00 0.08 (0.056–0.11) 12.40
(9.16–17.82)
    3–4 d 0.43 (0.31–0.54) 0.85 (0.72–0.98) 0.90 (0.85–0.95) 1.00 0.33 (0.231–0.43) 3.06
(2.32–4.33)
>5 d 0.67 (0.46–0.88) 0.85 (0.72–0.98) 0.90 (0.85–0.95) 1.00 0.51 (0.339– 0.70) 1.97
(1.42–2.95)
 Without  blood
  1–2  d 0.10 (0.07–0.14) 0.069 (0.02– 0.12) 0.90 (0.85–0.95) 1.00 0.01 (0.002–0.01) 154.17
(89.31–397.59)
  3–4  d 0.43  (0.31–0.54) 0.185  (0.071–
0.36)
0.90 (0.85–0.95) 1.00 0.07 (0.009–0.15) 14.15
(6.80–73.32)
>5 d 0.67 (0.46–0.88) 0.400 (0.133–
0.67)
0.90 (0.85–0.95) 1.00 0.24 (0.068–0.44) 4.25
(2.25–13.36)
STEC in South Australia 
 With  blood
  1–2  d 0.10 (0.07–0.14) 0.85 (0.72–0.98) 0.88 (0.83–0.93) 1.00 0.08 (0.0.05–0.11) 13.02
(9.50–18.37)
    3–4 d 0.43 (0.31–0.54) 0.85 (0.72–0.98) 0.88 (0.83–0.93) 1.00 0.32 (0.22–0.42) 3.13
(2.36–4.45)
>5 d 0.67 (0.46–0.88) 0.85 (0.72–0.98) 0.88 (0.83–0.93) 1.00 0.50 (0.33–0.68) 2.02
(1.47–3.04)
 Without  blood
  1–2  d 0.10 (0.07–0.14) 0.07 (0.02–0.12) 0.88 (0.83–0.93) 1.00 0.01 (0.001–0.02) 157.18
(61.67–218.75)
    3–4 d 0.43 (0.31–0.54) 0.19 (0.071–0.36) 0.88 (0.83–0.93) 1.00 0.07 (0.01–0.14) 14.35
(7.38–64.34)
>5 d 0.67 (0.46–0.88) 0.40 (0.133–0.67) 0.88 (0.83–0.93) 1.00 0.23 (0.07–0.44) 4.31
(2.27–13.44)
*STEC, Shiga toxin–producing Esherichia coli; CrI, credible interval; NF, notification factor. 
†NF, product of a × b × c × d. 
‡Inverse of NF. Salmonella, Campylobacter, and Shiga Toxin–producing Infections
compromised. However, some differences appear to be so 
large that they are of interest nonetheless. When compared 
with multipliers for enteric diseases in other countries, Aus-
tralia’s estimates were most similar to the estimates in the 
United Kingdom that were derived from a cohort study. It 
was estimated that for every case reported to surveillance, 
3.2 cases of salmonellosis and 7.6 cases of campylobacteri-
osis existed in the community (5). However, the multiplier 
for salmonellosis in the United States has been estimated 
in the past at 39 (3,19), and the same factor was estimated 
in a recent US study (6). This recent study estimated the 
component probabilities of the notiﬁ  cation fraction by us-
ing data from a population survey of diarrhea from 1996 in 
which the proportion of case-patients who visited a doctor 
was 12%. More recent surveys in the United States have 
put this estimate at ≈20% (20). If 20% is now more ap-
propriate, then the US multiplier would reduce to ≈25. In 
the US study, blood in stool was found to be highly in-
ﬂ  uential on stool test ordering by doctors (100% vs. 18% 
requested stool tests, depending on blood in stool) and not 
so inﬂ  uential on the probability of a case-patient visiting a 
doctor (15% vs. 12%), which was similar to our Australian 
study ﬁ  ndings. The US study did not report duration as a 
predictor of visiting a doctor and of having a stool test. Be-
cause salmonellosis frequently lasts >5 days, adjusting for 
duration had a marked impact on our multiplier, reducing it 
considerably. If a similar inﬂ  uence of duration on visiting 
a doctor and ordering stool tests exists in the United States, 
and the symptom proﬁ  le of salmonellosis is similar in the 
2 countries, then the US multiplier would likely be further 
reduced.
The choice of the case deﬁ  nition of diarrheal illness 
used in population studies may also have affected calcula-
tions for the multipliers when the method of component 
probabilities was used. If the case deﬁ  nition itself includes 
features of severity that are predictors of visiting a doctor 
or of having a stool test, this may affect the proportion of 
cases that undergo these steps, thereby affecting the com-
ponent probabilities used to calculate the multiplier. The 
laboratory sensitivity testing that provided another com-
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Table 4. Severity-specific underreporting for salmonellosis, campylobacteriosis, and STEC infections* 
Condition/severity category Symptom multiplier† (95% CrI)
No. reported cases in severity 
category, in hundreds (95% CrI) 
No. cases in the community for 
every 100 reported‡  (95% CrI) 
Salmonellosis
 With  blood
   1–2  d 11.39 (8.49–16.36) 1 (0–3) 12.7 (0.8–32.1)
    3–4 d 2.82 (2.17–3.98) 7 (5–10) 19.9 (12.6–30.9)
> 5 d 1.81 (1.33–2.72) 42 (37–47) 76.6 (54.3–116.0)
 Without  blood
   1–2  d 143.29 (83.30–371.0) 2 (1–4) 282.6 (50.4–870.3)
    3–4 d 13.06 (6.37–67.83) 7 (5–10) 91.8 (40.3–533.5)
>5 d 3.93 (2.10–11.92) 41 (36–46) 160.8 (85.8–513.8)
 Overall 100 695  (399–1,643)
Campylobacteriosis 
 With  blood
    1–2 d 12.40 (9.16–17.82) 2(1–3) 24.8 (16.3–38.6)
    3–4 d 3.06 (2.32–4.33) 8(6, 10) 24.3 (15.8–36.9)
>5 d 1.97 (1.42–2.95) 34 (31, 37) 67.92 (48.5–106.3)
 Without  blood
   1–2  d 154.17 (89.31–397.59) 3 (2–4) 475.7 (250.6–1,234.3)
    3–4 d 14.15 (6.80–73.32) 10 (8–12) 139.0 (68.7–739.7)
>5 d 4.25 (2.25–13.36) 43 (40–46) 183.4 (97.9–578.1)
 Overall 100 1001  (664–2,251)
STEC in South Australia 
 With  blood
   1–2  d 13.02 (9.50–18.37) 0 0
    3–4 d 3.13 (2.36–4.45) 18 (6–30) 51.6 (16.2–101.2)
>5 d 2.02 (1.47–3.04) 68 (50–87) 123.5 (74.9–212.9)
 Without  blood
   1–2  d 157.18 (61.67–218.75) 3 (1–5) 432.5 (142.4–1,220.1)
    3–4 d 14.35 (7.38–64.34) 6(1–11) 78.0 (13.6–400.1)
>5 d 4.31 (2.27–13.44) 6 (1–11) 2-3.0 (2.67–91.7)
  Overall 13.02 (9.50–18.37) 100 815 (330–7,514)
*STEC, Shiga toxin–producing Esherichia coli.
†Number of cases in the community for every notification. 
‡Product of previous 2 columns. RESEARCH
ponent probability may also affect the calculation of the 
multipliers. The quality assurance testing mimics some of 
the transport issues that occur in real life, but it probably 
represent a “best cases scenario” in which a patient sheds 
microorganisms at the time of collection, and good trans-
port methods are available.
In addition to unavoidable uncertainty due to paucity 
of data, methodologic differences in each study, combined 
with differences in surveillance systems, can make interna-
tional comparisons of disease incidence difﬁ  cult. However, 
applying the multiplier for each country leads to an estimate 
of community incidence that is likely to make comparisons 
more meaningful than simply comparing notiﬁ  cation rates. 
The notiﬁ  cation rates of salmonellosis in each country are 
currently ≈70/100,000 population for the United Kingdom 
(5), 38/100,000 for Australia, and 12/100,000 (21) for 
the United States. Applying the underreporting factors of 
3, 39, and 7 for the United Kingdom, United States, and 
Australia gives estimates of annual community incidence 
of ≈220/100,000, ≈470/100,000, and ≈262/100,000 (95% 
CrI 150–624), respectively. If more recent estimates of the 
proportion of case-patients who visit a doctor are used to 
calculate the underreporting factor in the United States, and 
a factor of 25 were applied to the number of notiﬁ  cations, 
the US rate becomes 300/100,000.
To validate results or assess the potential degree of 
error, another useful approach is to use differing methods 
and compare results in the same country. In Australia, 1 
other possible method is to use results from an Australian 
cohort study of diarrheal disease (22). The study was a ran-
domized controlled trial, conducted for 18 months, that as-
sessed the health impact of water quality and treatment in 
Melbourne, Victoria, in 1999. Of 795 stool samples tested, 
9 cases of salmonellosis (0.003 per person-year) and 24 
cases of campylobacteriosis (0.007 per person-year) were 
identiﬁ  ed. When these data are extrapolated to the notiﬁ  -
cations in Victoria, the community-to-notiﬁ  cation ratios 
are 12.6 for salmonellosis and 9.3 for campylobacteriosis, 
which are comparable to our estimated multipliers of 7 
(95% CrI 4–16) for salmonellosis and 10 (95% CrI 7–22) 
for campylobacteriosis.
Assessment of the functionality of surveillance is 
likely to lead to more effective control of disease in the 
community, and multipliers are 1 measure of the quality 
of surveillance systems. The relatively low ratio between 
reported enteric cases and the number of community cases 
in Australia suggests that the surveillance system is work-
ing reasonably effectively and therefore is likely to detect 
outbreaks.
This study provides an estimate of the community inci-
dence of 3 important foodborne diseases in Australia. Such 
estimates are important in public health to assess the eco-
nomic and human cost of these diseases and to help set pri-
orities. The estimates in this study show that salmonellosis, 
campylobacteriosis, and STEC have considerable effects in 
the community, most of which go unreported. Calculation 
of multipliers for other diseases would also be worthwhile 
to inform public health practice.
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